Closed consultations

  • Public consultation on items to be considered by the PBAC (July 2023)

    Consultation has opened for the July 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. How to provide input Input can be submitted via the online... More
    Closed 24 May 2023
  • Public consultation on applications to be considered by the MSAC PASC (April 2023)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2023. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications... More
    Closed 10 March 2023
  • Public consultation on applications to be considered by the MSAC (March 2023)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 30 - 31 March 2023. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications will proceed to MSAC in... More
    Closed 10 February 2023
  • Conversations for Change - Expressions of Interest in joining a Community Conversation

    The views and experiences of patients (consumers) and their carers on medicines and medical services and products play an important part in informing advice to the Australian Government on what should be provided. A process called health technology assessment (HTA) is used to inform this advice and includes consideration of the views and experiences of patients and carers. The Office of Health Technology Assessment’s (OHTA) Consumer Evidence and Engagement Unit (CEEU) is looking... More
    Closed 22 January 2023
  • Conversations for Change Consultation Survey

    The views and experiences of patients (consumers) and their carers on medicines and medical services and products play an important part in informing advice to the Australian Government on what should be provided. A process called health technology assessment (HTA) is used to inform this advice and includes consideration of the views and experiences of patients and carers. The Office of Health Technology Assessment’s (OHTA) Consumer Evidence... More
    Closed 22 January 2023
  • Public consultation on applications to be considered by the MSAC PASC (December 2022)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 8-9 December 2022. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications... More
    Closed 4 November 2022
  • Register for the HTA Consumer Symposium 2022, 18-19 October 2022

    The Health Technology Assessment (HTA) Consumer Consultative Committee (CCC) is hosting its second Symposium “Conversations for Change” for health consumers and health consumer organisations with an interest in HTA. Over two half-days, the Symposium will explore the evolving role of consumers in the HTA process. Tuesday 18 October: 1.30pm – 5.30pm (AEDT), and Wednesday 19 October: 10.30am – 2.30pm (AEDT) ... More
    Closed 17 October 2022
  • Public consultation on applications to be considered by the MSAC (Nov 2022)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 24-25 November 2022. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. Consultation input must be received by no later than Friday, 7 October 2022 for it to be... More
    Closed 7 October 2022
  • Public consultation on items to be considered by the PBAC (November 2022)

    Consultation is now open for items listed on the November 2022 PBAC agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Input can be submitted via the online survey. A copy of the questions asked in the survey... More
    Closed 21 September 2022
  • Public consultation on applications to be considered by the MSAC PASC (August 2022)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 11-12 August 2022. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications... More
    Closed 8 July 2022
  • Public consultation on applications to be considered by the MSAC (July 2022)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 28-29 July 2022. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. Consultation input must be received by no later than Friday, 10 June 2022 for it to be considered by... More
    Closed 10 June 2022
  • Review of discount rate in the PBAC guidelines - Phase 2 consultation

    The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, advice was sought from the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best... More
    Closed 1 June 2022
  • Public consultation on items to be considered by the PBAC (July 2022)

    Consultation is now open for items listed on the July 2022 PBAC agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Input can be submitted via the online survey. A copy of the questions asked in the survey can... More
    Closed 25 May 2022
  • Review of discount rate in the PBAC guidelines - Phase 1 consultation

    The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, the Minister for Health has sought the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best... More
    Closed 29 April 2022
  • Public consultation on items to be considered by the PBAC (May 2022 Intracycle Meeting)

    PBAC Intracycle meetings are held between the main PBAC meetings. Submission items considered by the PBAC at these meetings typically relate to matters arising from previous submissions but can also relate to new medicines. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. All public consultation inputs are considered by the PBAC when... More
    Closed 8 April 2022
  • Public consultation on applications to be considered by the MSAC PASC (April 2022)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2022. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications... More
    Closed 11 March 2022
  • Public consultation on applications to be considered by the MSAC (March/April 2022)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 31 March - 1 April 2022. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications will proceed to MSAC in March/April... More
    Closed 11 February 2022
  • Public consultation on items to be considered by the PBAC (March 2022)

    Consultation is now open for items listed on the March 2022 PBAC agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Input can be submitted via the online survey which includes an option to upload a file. You... More
    Closed 27 January 2022
18 results. Page 1 of 1